百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ONC 百济神州

已收盘 05-09 16:00:00 EDT

231.99

-3.95

-1.67%

盘后228.20

-3.79-1.63%

17:17 EDT

最高238.93	最低230.23	成交量37.57万
今开234.59	昨收235.94	日振幅3.69%
总市值250.43亿	流通市值182.91亿	总股本1.08亿
成交额8,721万	换手率0.48%	流通股本7,885万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":231.99,"timestamp":1746820800000,"preClose":235.94,"halted":0,"volume":375689,"hourTrading":{"tag":"盘后","latestPrice":228.2,"preClose":231.99,"latestTime":"17:17 EDT","volume":56602,"amount":13129613.59,"timestamp":1746825449798},"delay":0,"floatShares":78845302,"shares":107947006,"eps":-3.70325,"marketStatus":"已收盘","change":-3.95,"latestTime":"05-09 16:00:00 EDT","open":234.59,"high":238.93,"low":230.23,"amount":87206253.10528001,"amplitude":0.036874,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":5,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":235.94,"preHourTrading":{"tag":"盘前","latestPrice":232.7,"preClose":235.94,"latestTime":"09:02 EDT","volume":7106,"amount":1676581.96552,"timestamp":1746795722635},"postHourTrading":{"tag":"盘后","latestPrice":228.2,"preClose":231.99,"latestTime":"17:17 EDT","volume":56602,"amount":13129613.59,"timestamp":1746825449798},"volumeRatio":0.756008,"impliedVol":0.3961,"impliedVolPercentile":0.125},"requestUrl":"/m/hq/s/ONC","defaultTab":"news","newsList":[{"id":"2534612489","title":"百济神州盘前涨超1% 机构指公司1Q25收入符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2534612489","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534612489?lang=zh_cn&edition=full","pubTime":"2025-05-09 20:30","pubTimestamp":1746793813,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州 盘前涨超1%，截至发稿，报239美元。消息面上，招银国际研报指，百济神州公布的1Q25产品收入为11.1亿美元，同比增长48%，环比下降1%。浦银国际表示，百济神州1Q25收入符合预期，提前实现季度GAAPOP盈利及净盈利略好于预期，公司维持全年指引不变。如该行所料，产品毛利率为85.1%，同比上升明显，环比较为稳定，主要受益于泽布替尼海外销售持续增长推动，以及生产效率的提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050920304797547f1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050920304797547f1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526"],"gpt_icon":0},{"id":"2534125994","title":"浦银国际证券给予百济神州买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2534125994","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534125994?lang=zh_cn&edition=full","pubTime":"2025-05-09 14:54","pubTimestamp":1746773647,"startTime":"0","endTime":"0","summary":"浦银国际证券05月08日发布研报称，给予百济神州（688235.SH，最新价：244元）买入评级。评级理由主要包括：1）1Q25收入符合预期，提前实现季度GAAPOP盈利及净盈利略好于预期，公司维持全年指引不变；2）泽布替尼海外销售持续高速增长；3）毛利率符合预期，经营效率持续提升。风险提示：泽布替尼海外销售增速未如预期；核心研发管线临床/审批延误或数据不及预期等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505093400575973.html","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505093400575973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06160","ONC"],"gpt_icon":0},{"id":"2534111882","title":"百济神州5月8日成交额为1.07亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534111882","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534111882?lang=zh_cn&edition=full","pubTime":"2025-05-09 10:25","pubTimestamp":1746757517,"startTime":"0","endTime":"0","summary":"美东时间2025年5月8日，百济神州成交额为1.07亿美元，成交额较昨日减少31.95%，当日成交量为45.66万股。百济神州于2025年5月8日涨1.59%，报235.94美元，该股过去5个交易日跌7.71%，年初至今涨27.74%，过去60日涨6.65%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509102527a477819b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509102527a477819b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526"],"gpt_icon":0},{"id":"2534154571","title":"加拿大皇家银行：维持BeiGene(ONC.US)评级，由优于大市调整至优于大市评级, 目标价由312.00美元调整至311.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2534154571","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534154571?lang=zh_cn&edition=full","pubTime":"2025-05-09 01:12","pubTimestamp":1746724339,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：维持BeiGene(ONC.US)评级，由优于大市调整至优于大市评级, 目标价由312.00美元调整至311.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/09011250242562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06160","ONC"],"gpt_icon":0},{"id":"2533535691","title":"百济神州一季度实现盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2533535691","media":"广州日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533535691?lang=zh_cn&edition=full","pubTime":"2025-05-08 23:40","pubTimestamp":1746718834,"startTime":"0","endTime":"0","summary":"百济神州港股、美股、A股三日前地同时发布的2025年第一季度财报透露的信息：公司总营收达到80.20亿元，同期相比增长了48.64%；利润总额比去年同期多了近20亿元，由亏转盈。公司在美国通用会计准则下，首次实现季度盈利。百济神州的核心产品泽布替尼、替雷利珠单抗的销售额暴涨。今年一季度，泽布替尼全球销售额达56.92亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505083399819516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","LU0588546209.SGD","BK1588","LU0307460666.USD","BK1583","LU2328871848.SGD","06160","BK1161","ONC","LU1969619763.USD","BK1500"],"gpt_icon":0},{"id":"2533899751","title":"百济神州(ONC)盘前涨超2% 机构看好泽布替尼2Q25环比持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2533899751","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533899751?lang=zh_cn&edition=full","pubTime":"2025-05-08 19:44","pubTimestamp":1746704652,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州(ONC)盘前涨超2%，截至发稿，报236.96美元。消息面上，海通国际研报指出，1Q25百济神州实现归母净利润127万美元（1Q24亏损2.5亿美元)，首次实现单季度经常性业务盈利（US GAAP 口径）。管理层维持全年49-53亿美元收入指引不变。该行认为百济神州的业绩整体符合预期。海外收入增长拉动公司业绩扭亏。1Q25公司产品收入同比增长48.4%至11.1亿美元，主要得益于泽布替尼的海外销售增长。看好泽布替尼2Q25环比持续增长，泽布替尼距离销售峰值仍有较大空间。维持“优于大市”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/N2NlYWIzMDQ5MjY5YzU0NWM0NDMwZTE4ZDQ3MjY3ODIxNTA5MDg=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/N2NlYWIzMDQ5MjY5YzU0NWM0NDMwZTE4ZDQ3MjY3ODIxNTA5MDg=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"288322","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","06160","LU1969619763.USD","BK1500","LU2328871848.SGD","LU0307460666.USD","BK1161","BK1588","BK1583","688235","BK0239","LU0588546209.SGD","BK4139"],"gpt_icon":0},{"id":"2533890882","title":"“扭亏”上岸，百济一季度营收80亿，新“一哥”诞生？","url":"https://stock-news.laohu8.com/highlight/detail?id=2533890882","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533890882?lang=zh_cn&edition=full","pubTime":"2025-05-08 17:34","pubTimestamp":1746696884,"startTime":"0","endTime":"0","summary":"2025年一季度，泽布替尼在美国销售额总计40.41亿元，同比增长61.9%。2024年年初，百济神州公布全年业绩情况，泽布替尼2023年全年全球销售额达13亿美元，成为“首个国产十亿美元分子”。然而，百济神州的泽布替尼仅用了短短四年时间，便跻身于“重磅炸弹”药物的行列，展现了其非凡的市场潜力和影响力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508174243a6d77556&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508174243a6d77556&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160"],"gpt_icon":0},{"id":"2533226619","title":"百济神州：1Q25首盈利 目标价 182.35 港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533226619","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533226619?lang=zh_cn&edition=full","pubTime":"2025-05-08 14:21","pubTimestamp":1746685305,"startTime":"0","endTime":"0","summary":"【5 月 8 日，浦银国际研报：百济神州1Q25 首次实现单季度经常性业务盈利】1Q25 百济神州实现归母净利润 127 万美元，1Q24 亏损 2.5 亿美元。管理层维持全年 49 - 53 亿美元收入指引不变。1Q25 公司产品收入同比增长 48.4%至 11.1 亿美元，主要因泽布替尼海外销售增长。该行看好泽布替尼 2Q25 环比持续增长，其距销售峰值仍有较大空间。予目标价 182.35 元港币，维持“优于大市”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050815252394f02da1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050815252394f02da1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC"],"gpt_icon":0},{"id":"2533592300","title":"百济神州2025Q1：替雷利珠单抗销售额12亿元，同比增长19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533592300","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533592300?lang=zh_cn&edition=full","pubTime":"2025-05-08 11:37","pubTimestamp":1746675469,"startTime":"0","endTime":"0","summary":"5月7日，百济神州发布2025Q1财报，2025年第一季度总收入为80.48亿元，同比增长50.2%，总收入的增长主要得益于百悦泽在美国和欧洲的销售额增长。其产品收入为79.85亿元，同比增长49.9%。血液肿瘤领域产品泽布替尼在第一季度实现全球销售额总计56.92亿元，同比增长63.7%。此外，百济神州透露预计将于2025 年下半年取得FDA和EC对泽布替尼片剂新剂型上市申请的批准。从安进公司获得授权许可的产品和百泽安的销售额为12.45亿元，同比增长19.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508142221a476447d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508142221a476447d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","ONC","688235","06160"],"gpt_icon":0},{"id":"2533085920","title":"每日医刻｜司美格鲁肽一季度销量全球第一；百济神州 Q1：首次实现季度盈利！","url":"https://stock-news.laohu8.com/highlight/detail?id=2533085920","media":"财健道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533085920?lang=zh_cn&edition=full","pubTime":"2025-05-08 10:59","pubTimestamp":1746673165,"startTime":"0","endTime":"0","summary":"将“财健道”设为星标持续关注，不错过好看每日医刻1司美格鲁肽一季度销量全球第一5月7日，诺和诺德公布2025年一季度业绩，总营收780.87亿丹麦克朗，约112.16亿美元，同比增长18%。4百济神州 Q1：首次实现季度盈利5 月 7 日，百济神州发布 2025 年第一季度美股业绩报告及 A 股业绩快报，实现营收 80.48 亿元，同比增长 50.2%。财务表现方面，2025 年第一季度，百济神州凭借全球收入的快速增长和经营费用的有效管理，在盈利方面再次取得重大进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508155200a6d74f34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508155200a6d74f34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688235","BK0239","06160"],"gpt_icon":0},{"id":"2533917313","title":"百济神州：泽布替尼新剂型预计今年下半年在欧美获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2533917313","media":"医药魔方","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533917313?lang=zh_cn&edition=full","pubTime":"2025-05-08 10:35","pubTimestamp":1746671753,"startTime":"0","endTime":"0","summary":"目前泽布替尼获批的剂型为胶囊。百济神州已计划对R/R MCL适应症的II期临床试验进行数据读出并有望针对该项适应症在2025年下半年递交全球加速上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508105036a47617c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508105036a47617c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","LU1969619763.USD","BK1588","BK1500","LU2328871848.SGD","BK1583","LU0307460666.USD","ONC","06160","BK1161","688235"],"gpt_icon":0},{"id":"2533146059","title":"百济神州5月7日成交额为1.58亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533146059","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533146059?lang=zh_cn&edition=full","pubTime":"2025-05-08 10:21","pubTimestamp":1746670879,"startTime":"0","endTime":"0","summary":"美东时间2025年5月7日，百济神州成交额为1.58亿美元，成交额较昨日减少33.37%，当日成交量为67.72万股。百济神州于2025年5月7日跌3.93%，报232.25美元，该股过去5个交易日跌10.61%，年初至今涨25.74%，过去60日涨5.73%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508102121a6d70751&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508102121a6d70751&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2533914871","title":"两大千亿营收巨头领跑！云南白药首破400亿，百济神州、恒瑞大涨，人福、片仔癀……创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2533914871","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533914871?lang=zh_cn&edition=full","pubTime":"2025-05-08 10:08","pubTimestamp":1746670080,"startTime":"0","endTime":"0","summary":"从营收增速来看，百济神州、新和成、恒瑞医药、华润三九等5家均有双位数增长；智飞生物跌幅最大，超过50%。上海医药、九州通两家千亿营收龙头继续领跑，重药控股、南京医药、国药股份均超过500亿元。创新高，云南白药首破400亿此外，人福医药、恒瑞医药、科伦药业、片仔癀等超20家创新高。其中，国药股份首次突破500亿元，云南白药首次突破400亿元，百济神州、新和成和鹭燕医药首次突破200亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050810152094efe52a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050810152094efe52a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600276","600436","688235","06160","ONC","000538"],"gpt_icon":0},{"id":"2533198039","title":"【券商聚焦】海通国际维持百济神州(06160)“优于大市”评级 指其业绩整体符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2533198039","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533198039?lang=zh_cn&edition=full","pubTime":"2025-05-08 09:55","pubTimestamp":1746669314,"startTime":"0","endTime":"0","summary":"金吾财讯 | 海通国际发研指，1Q25百济神州 实现收入11.2亿美元，其中产品收入11.1亿美元。管理层维持全年49-53亿美元收入指引不变。该行认为百济神州的业绩整体符合预期。该行指，1Q25公司产品收入同比增长48.4%至11.1亿美元，主要得益于泽布替尼的海外销售增长。分产品来看：泽布替尼实现收入7.9亿美元。截至1Q25公司在手现金及现金等价物25.2亿美元。基于WACC9%，永续增长率4.0%（均不变），对应目标价182.35元港币，维持“优于大市”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1958309","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","ONC","688235"],"gpt_icon":0},{"id":"2533918950","title":"金十数据整理：每日港股市场要闻速递（5月8日 周四）","url":"https://stock-news.laohu8.com/highlight/detail?id=2533918950","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533918950?lang=zh_cn&edition=full","pubTime":"2025-05-08 09:13","pubTimestamp":1746666783,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1578","LU0516422952.EUR","ZK","LU1064130708.USD","BK1119","06160","00175","LU2039709279.SGD","LU1497733557.USD","82020","BK1227","LU1226287875.USD","688235","LU0320764599.SGD","LU1497734951.SGD","BK1610","06158","BK1152","00168","600735","LU0708995583.HKD","IE00B031J352.USD","GELYY","CHL","80883","LU0251143458.SGD","ONC","ANPDY","02020","07226","BK1539","600941","80175","HSCEI","01541","EURmain","EUO","03301","LU0605514214.HKD","LU0149721374.USD","00941","HSTECH","LU0164880469.USD","EVS.SI","YANG","FXE","MEURmain","LU1226287529.USD","IE00BZ08YR35.GBP","01310"],"gpt_icon":0},{"id":"2533303749","title":"百济首次实现季度营业利润扭亏，泽布替尼销售额近57亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533303749","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533303749?lang=zh_cn&edition=full","pubTime":"2025-05-07 22:50","pubTimestamp":1746629428,"startTime":"0","endTime":"0","summary":"2025年第一季度，百济神州实现营收80.48亿元，同比增长50.2%，其中产品收入79.85亿元，同比增长49.9%。根据A股业绩快报，百济神州实现营业利润、利润总额由亏损转为盈利，分别为1.51亿元、1.5亿元。目前，泽布替尼在全球75个市场获批，同时本季度在11个市场新增纳入或扩大报销范围。今年第一季度，泽布替尼全球销售额为56.92亿元，同比增长63.7%。百济神州称，泽布替尼本季度首次位居美国BTK抑制剂领域市场份额首位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507225321a475803f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507225321a475803f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688235","BK4139"],"gpt_icon":0},{"id":"2533932462","title":"百济神州一季度亏损大幅收窄 国内BTK抑制剂销售加速、PD-1销售减速","url":"https://stock-news.laohu8.com/highlight/detail?id=2533932462","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533932462?lang=zh_cn&edition=full","pubTime":"2025-05-07 22:41","pubTimestamp":1746628873,"startTime":"0","endTime":"0","summary":"作为国内创新药龙头企业，百济神州目前有3款主要自研产品，分别为BTK抑制剂泽布替尼、PD-1单抗替雷利珠单抗和PARP抑制剂帕米帕利。对于一季度的产品收入增长，公司归因于百悦泽、百泽安及安进授权产品的销售增长。具体来说，今年第一季度，百悦泽全球销售额总计56.92亿元，同比增长63.7%。而在竞争更为激烈的国内PD-1单抗市场中，百泽安实现销售额12.45亿元，同比增长19.3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050722420597521340&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050722420597521340&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","LU1169589451.USD","06160","BK4023","LU1169590202.USD","ONC","BK4139","PD"],"gpt_icon":0},{"id":"2533939776","title":"百济神州一季度产品收入近80亿元：跨越“创新鸿沟”，全球化突围成盈利胜负手","url":"https://stock-news.laohu8.com/highlight/detail?id=2533939776","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533939776?lang=zh_cn&edition=full","pubTime":"2025-05-07 21:53","pubTimestamp":1746625980,"startTime":"0","endTime":"0","summary":"具体来看，业绩快报显示，百济神州实现营收80.48亿元，同比增长50.2%。基于此，百济神州预计2025年全年营业收入将介于人民币 352亿元至 381 亿元之间。目前，泽布替尼在全球75个市场获批，同时本季度在11个市场新增纳入或扩大报销范围。目前，该产品已在全球46个市场获批上市，超150万例患者接受治疗。在海外市场，百济神州在2024年10月初高调宣布，其PD-1抗癌药物替雷利珠单抗在获得FDA批准六个多月后，终于在美国正式上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507215548a4757443&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507215548a4757443&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","ONC","BK4139"],"gpt_icon":0},{"id":"2533936482","title":"年内股价涨幅超三成的百济神州，一季度营业利润扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2533936482","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533936482?lang=zh_cn&edition=full","pubTime":"2025-05-07 21:40","pubTimestamp":1746625243,"startTime":"0","endTime":"0","summary":"今年以来，百济神州（ONC.NS、06160.HK、688235.SH）美股、港股、A股三地的股价累计涨幅均超过30%。5月7日晚间，百济神州公布的2025年第一季度美股业绩报告及A股业绩快报显示，公司业绩有继续向好趋势。百济神州A股业绩快报显示，2025年第一季度，公司实现营业利润、利润总额由亏损转为盈利，均实现盈利1.5亿元左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505073398404544.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505073398404544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","LU2328871848.SGD","BK1583","BK1161","LU1969619763.USD","LU0588546209.SGD","BK4139","BK1588","BK1500","LU0307460666.USD","06160"],"gpt_icon":0},{"id":"1155121510","title":"异动解读 | 百济神州一季度业绩改善但盘前大跌5.25%，市场反应存疑","url":"https://stock-news.laohu8.com/highlight/detail?id=1155121510","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155121510?lang=zh_cn&edition=full","pubTime":"2025-05-07 20:49","pubTimestamp":1746622160,"startTime":"0","endTime":"0","summary":"尽管百济神州发布的2025年第一季度财报显示业绩明显改善，但该公司股价今日盘前却大跌5.25%，引发市场关注。根据公司最新发布的财报，百济神州2025年第一季度实现营业总收入80.48亿元，同比增长50.2%；其中产品收入79.85亿元，同比增长49.9%。然而，尽管财务表现显著改善，百济神州股价在盘前交易中却出现大幅下跌。市场分析人士指出，创新药板块近期持续调整，可能对百济神州股价造成压力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ONC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":-0.0771},{"period":"1month","weight":0.1267},{"period":"3month","weight":0.0557},{"period":"6month","weight":0.1483},{"period":"1year","weight":0.4348},{"period":"ytd","weight":0.2774}],"compareEarnings":[{"period":"1week","weight":0.0118},{"period":"1month","weight":0.1381},{"period":"3month","weight":-0.0594},{"period":"6month","weight":-0.0554},{"period":"1year","weight":0.0926},{"period":"ytd","weight":-0.0359}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BeiGene Ltd是一家全球生物技术公司，致力于为全球癌症患者发现和开发肿瘤治疗方法。该公司已发现并开发三种批准药物，包括BRUKINSA，一种布鲁顿酪氨酸激酶的小分子抑制剂，用于治疗各种血癌；TEVIMBRA（tislelizumab），一种抗PD-1抗体免疫疗法，用于治疗各种实体瘤和血癌；以及是聚ADP核糖聚合酶1(PARP1)和PARP2的选择性小分子抑制剂pamiparib。该公司已获得在美国、中华人民共和国（中国）、欧盟、英国、加拿大、澳大利亚和其他国际市场销售BRUKINSA，在欧盟和中国销售替雷利珠单抗，以及在中国销售帕米帕尼的批准。它还专注于在Amgen Inc独家授权下在中国商业化癌症药物，如XGEVA、BLINCYTO、KYPROLIS等。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.079635},{"month":2,"riseRate":0.666667,"avgChangeRate":0.038229},{"month":3,"riseRate":0.4,"avgChangeRate":-0.025903},{"month":4,"riseRate":0.4,"avgChangeRate":0.021288},{"month":5,"riseRate":0.4,"avgChangeRate":-0.022804},{"month":6,"riseRate":0.555556,"avgChangeRate":0.015441},{"month":7,"riseRate":0.777778,"avgChangeRate":0.136456},{"month":8,"riseRate":0.555556,"avgChangeRate":0.036185},{"month":9,"riseRate":0.555556,"avgChangeRate":0.064683},{"month":10,"riseRate":0.555556,"avgChangeRate":0.004837},{"month":11,"riseRate":0.555556,"avgChangeRate":0.060012},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.03651}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,ONC,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}